Cibus Narrows Q3 Loss but Cash Runs to Early Q1 2027
CBUS is trading near its 52-week low of $1.07 (0.9% above the low).
Summary
Cibus posted a Q3 net loss of $21.9 million, or $0.29 per share, versus $24.3 million a year ago, as R&D spending fell to $7.9 million from $10.8 million on lower headcount and facility closures. The problem is the balance sheet: cash stood at just $10.7 million on September 30, and management says that funds operations only into early Q1 2027 without new financing. Nine-month operating cash burn was $30.2 million, about 19% better than last year, and the company still targets roughly $35 million annualized net cash use exiting 2026. On the commercial side, Rice herbicide-tolerance traits are now being tested in customer Interoc's own varieties in Ecuador with results due Q1 2027, and Cibus started manufacturing its first two biofragrance products, a program it pegs at up to about $100 million in peak annual revenue. With the stock near its 52-week low and a going-concern overhang, the near-term story is funding, not pipeline progress. Watch for a definitive Interoc commercialization agreement and any capital raise, given the $200 million shelf and $50 million ATM already in place.
At the time of this announcement, CBUS was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.3M. The 52-week trading range was $1.07 to $4.19. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.